Impact on health‐related quality of life and symptoms of anxiety and depression after 32 weeks of Dupilumab treatment for moderate‐to‐severe atopic dermatitis

Dupilumab is the first biological agent approved for treatment of moderate‐to‐severe atopic dermatitis (AD). Evidence of Dupilumab effectiveness on psychological outcomes beyond 16 weeks of treatment from real‐life settings is lacking. To evaluate the effectiveness of Dupilumab treatment up to 32 we...

Descripción completa

Detalles Bibliográficos
Autores principales: Miniotti, Marco, Lazzarin, Giulia, Ortoncelli, Michela, Mastorino, Luca, Ribero, Simone, Leombruni, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9286472/
https://www.ncbi.nlm.nih.gov/pubmed/35218275
http://dx.doi.org/10.1111/dth.15407

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9286472/
https://www.ncbi.nlm.nih.gov/pubmed/35218275
http://dx.doi.org/10.1111/dth.15407

Ejemplares similares